Follow The Filings

DGX Quest Diagnostics

Quest Diagnostics earnings company data as of 9:15 AM ET 10/23

  • 1 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 22 Oct EPS 2.85 3.00 Beat +5.3%
Rev — — —

Insider trades

Open-market buys and sales by DGX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DGX insider trades
  • None no insider bought on the open market
  • $240K sold by 1 insider outside a trading plan
  • $36.2M sold by 6 insiders under 10b5-1 plans
  1. J. E. Davis CEO
    Planned sale
    $2.4M 10,000 shares at $242.72 7.6% of stake
    Traded Sep 1 Filed Sep 3
  2. Michael E Prevoznik SVP & General Counsel
    Planned sale
    $5.5M 22,677 shares at $243.11 38% of stake
    Traded Aug 28 Filed Aug 31
  3. Mark E Delaney SVP & Chief Commercial Officer
    Planned sale
    $376K 1,600 shares at $235.18 13% of stake
    Traded Jul 28 Filed Jul 29
  4. Karthik Kuppusamy SVP, Clinical Solutions
    Planned sale
    $1.6M 8,147 shares at $200.00 38% of stake
    Traded Jun 4 Filed Jun 8
  5. J. E. Davis CEO
    Planned sale
    $1.9M 10,000 shares at $194.14 7% of stake
    Traded Jun 1 Filed Jun 2
  6. Catherine T. Doherty EVP, Regional Businesses
    Planned sale
    $1.1M 5,558 shares at $206.21 7.6% of stake
    Traded Mar 5 Filed Mar 6
  7. Michael E Prevoznik SVP & General Counsel
    Planned sale
    $800K 3,878 shares at $206.21 9.4% of stake
    Traded Mar 5 Filed Mar 6
  8. Patrick Plewman SVP for Diagnostic Services
    Planned sale
    $589K 2,855 shares at $206.21 16% of stake
    Traded Mar 5 Filed Mar 6
  9. Catherine T. Doherty EVP, Regional Businesses
    Planned sale
    $131K 632 shares at $207.73 0.9% of stake
    Traded Mar 3 Filed Mar 4
  10. Michael E Prevoznik SVP & General Counsel
    Planned sale
    $109K 526 shares at $207.73 1.4% of stake
    Traded Mar 3 Filed Mar 4
  11. J. E. Davis CEO
    Planned sale
    $2.1M 10,000 shares at $212.52 7.9% of stake
    Traded Mar 2 Filed Mar 4
  12. Patrick Plewman SVP for Diagnostic Services
    Planned sale
    $85K 410 shares at $207.73 2.6% of stake
    Traded Mar 3 Filed Mar 4
  13. Catherine T. Doherty EVP, Regional Businesses
    Planned sale
    $294K 1,433 shares at $204.83 2.1% of stake
    Traded Feb 19 Filed Feb 20
  14. Patrick Plewman SVP for Diagnostic Services
    Planned sale
    $196K 958 shares at $204.83 5.7% of stake
    Traded Feb 19 Filed Feb 20
  15. Michael E Prevoznik SVP & General Counsel
    Planned sale
    $228K 1,111 shares at $204.83 2.8% of stake
    Traded Feb 19 Filed Feb 20

Also filed in the last 12 months, not counted as buying or selling: 33 stock grants, 32 share withholdings for taxes, 16 other transactions, 8 option exercises, 1 gift, and 1 sale to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
8-K 8.01
8-K 2.02,9.01
8-K 5.02
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.07
8-K 1.01,9.01
8-K 8.01,9.01
SCHEDULE 13G —
SCHEDULE 13G —
424B2
424B2

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.